ClinicalTrials.gg
RecruitingNCT07736937OCUpdated Sep 1, 2026

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

A Phase 1/2 interventional study of TUB-040 + Carbo + BEV in Ovarian Cancer, sponsored by Tubulis GmbH. Recruiting at 8 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Tubulis GmbH · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2026, registered Jul 2026).
  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 197 studies in Ovarian Neoplasms with a site in Belgium — 33 open to participants now, 56 under way, 21 of them phase 3. Ovarian Neoplasms · Belgium.

Planned enrollment
143rd of 177
72 · median 215
Started
2026
with 6 others
Phase 1/2
28 of 197
8 open now
Primary completion
2028-03
later than 35 of 55 live
Registered
195th of 197
by date

Among the 197 studies in Ovarian Neoplasms with a site in Belgium, this one is the 143rd largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2026, is one of 28 in phase 1/2, reaches primary completion later than 35 of the 55 other live ones, and was the 195th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

33 of the 197 studies in Ovarian Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Ovarian Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer.

This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female ≥ 18 years of age at the time of the first screening visit
  2. (ECOG) performance status (PS) 0 or 1
  3. confirmed advanced high-grade serous or endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer.
  4. Have platinum-sensitive ovarian cancer (PSOC) defined as: Patients who had recurrences (radiologically confirmed) to platinum-based therapy and have responded to the last platinum therapy received before study entry and did not progress within 6 months (182 days) of the date of the last dose of platinum-based systemic treatment.
  5. Radiologically in at least 1 lesion by (RECIST) v 1.1, that can include a lesion in an irradiated field and that shows progression according to RECIST v1.1
  6. Patients must have progressed radiographically on or after their most recent line of anticancer therapy
  7. Adequate hematologic function as indicated by:

    1. counts ≥100,000/mm3 (no transfusion or growth factors, e.g., eltrombopag, romiplostim, or IL-11 within 4 weeks before first dose)
    2. ≥9.0 g/dL (no transfusion or growth factors e.g. erythropoietin (EPO), darbepoetin within 4 weeks before first dose or long-acting white blood cell growth factors within 20 days before first dose)
    3. (ANC) ≥1500/μL (no growth factors, e.g., granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF) within 4 weeks before first dose)
    4. (INR) ≤1.5 and activated partial thromboplastin time (aPTT) ≤1.5 × (ULN) in the absence of anticoagulation therapy. If patients are on anticoagulation therapy with a specific INR goal, INR should be within the therapeutic range for the medical indication.
  8. Adequate hepatic function defined as total level ≤1.5 × ULN, an (AST) level ≤2.5 × ULN, and an alanine aminotransferase (ALT) level ≤2.5 × ULN

    1. For documented Gilbert's Syndrome, a total bilirubin \<3 × ULN is accepted
    2. For patients with liver , AST and ALT \<5 × ULN is accepted
  9. Alkaline phosphatase \< 2.5 x ULN, except if there is an alternative explanation for ALP elevation rather than hepatic failure, such as the presence of bone metastasis
  10. Adequate renal function defined by ≥60 mL/min (according to the Chronic Kidney Disease Epidemiology Collaboration, CKD-EPI, formula [Appendix B]).
  11. Patients must be willing to sign an release form for research purposes and determination of biomarker (e.g., NaPi2b) expression. The patient must have an adequate tumor tissue sample available for biomarker assessment by the central laboratory. Mandatory is either a tissue (FFPE) block or a minimum of 6 freshly cut unstained sections based on the most recently available tumor sample. If no archival specimens are available, a new biopsy must be performed. For patients in which a fresh biopsy poses unacceptable clinical risk in the judgment of the treating investigator, enrollment may be considered on a case-by-case basis only after discussion with the Sponsor Medical Monitor.
  12. Resolution of all acute toxic effects of prior therapy or surgical procedures to Grade ≤1 including peripheral neuropathy (except alopecia, hyperpigmentation, or discoloration (incl. vitiligo) of the skin and nails, stable immune-related toxicity such as hypothyroidism on hormone) replacement, treatment on ≤10 mg daily prednisone (or equivalent)
  13. Patients with previous systemic topoisomerase 1 inhibitor treatment (e.g., Topotecan) or patients that are previously treated with ADCs are allowed (except for ADCs with a topoisomerase 1 inhibitor, such as SN38 or other camptothecin derivatives as payload or any ADC targeting NaPi2b)
  14. Completed washout of prior therapy:

    1. Systemic anti-neoplastic therapy: five half-lives or 4 weeks, whichever is shorter prior to first dose of study drug. Hormonal therapy is not considered anti-neoplastic therapy.
    2. Radiotherapy: last dose ≥ 2 weeks from first dose of study drug
    3. Completed major surgery at least 4 weeks prior from first dose of study drug and recovered from side effects to Grade ≤1.
  15. Viral infections:

    1. Patients who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B (HBV) anti-viral therapy for at least 4 weeks and have undetectable HBV viral load Note: Patients should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post-completion of study intervention.
    2. Patients with history of viral (HCV) infection are eligible if HCV viral load is undetectable at screening. Note: Patients must have completed curative anti-viral therapy at least 4 weeks before enrollment
  16. Women of (WOCBP) who are sexually active with a non-sterilized partner must use at least 1 highly effective method of (with a failure rate of ≤1% per year) from the time of screening and must agree to continue using such precautions until the end of exposure, plus at minimum 5 half-lives and 6 months after last dose of either TUB-040, carboplatin, or bevacizumab, whichever is later, in the case of patients of childbearing potential. Abstinence is acceptable only when this is in line with the preferred and usual lifestyle of the patient for the duration of the study treatment and the above-referred period after the end of the exposure. Periodic abstinence (e.g. calendar ovulation, symptom-thermal, post-ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception.

    Note: A pregnancy test (urine or serum test or per institutional guideline) 72 hours before enrollment is required in WOCBP. Within 72 hours before enrollment, if a positive urine pregnancy test result is confirmed using a serum test, then the patient should not be enrolled into the study. Pregnancy tests (urine or serum test per institutional guideline) should be performed within 72h and resulted prior to the administration of any study treatment, at End of Treatment, and during Follow-Up as mandated by the Schedule of Assessments. In Follow-Up, this is continued monthly for 5-half-lives + 6 months after the last dose of any drug under study, at minimum. Women who have undergone a hysterectomy and/or bilateral salpingo-oophorectomy are exempted from testing.

  17. Patients must agree to continue a highly effective contraceptive method, refrain from egg cell donation and breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment.

    Note: The half-life of TUB-040 is approximately 6 days.

  18. Female patients will be considered if they have undergone bilateral salpingectomy, and/or bilateral oophorectomy, and/or hysterectomy or have been amenorrheic for 12 months without an alternative medical cause (treatment with antihormonal therapies is considered an alternative medical cause). The following age specific requirements apply:

    1. Women \<50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all hormonal replacement therapy and/or if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution.
    2. Women ≥50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all hormonal replacement therapy or had radiation-induced menopause with most recent menses >1 year ago or had chemotherapy-induced menopause with most recent menses >1 year ago.
  19. In the opinion of the INV, the patient must be able to understand, must be willing to sign form (ICF) and comply with all study-related procedures, medication use, and evaluations.
  20. Patients must have 1-2 prior lines of systemic platinum therapy and have not progressed within 182 days after the date of the last dose of platinum.

    Notes:

    I. ± adjuvant is considered as one .

    II. Maintenance therapy (e.g., BEV, poly adenosine diphosphate-ribose polymerase inhibitors (PARPi)) does not count as a line of therapy.

    III. Prior treatment may include BEV

  21. Prior treatment with PARPi is required (for patients who were previously documented to be HRD positive or have a germline or somatic BRCA 1/2 mutation), if PARPi therapy was locally approved at the time of testing.

Exclusion criteria

Exclusion Criteria:

  1. Patients with clear-cell, mucinous histology, mixed histology with mucinous component, sarcoma, sarcomatous component, or low-grade ovarian cancer
  2. Patients with platinum ovarian cancer (OC) (Platinum refractory is defined as disease that has not responded to a primary platinum-based regimen or progressed within 30 days after primary platinum-based therapy) or platinum resistant ovarian cancer
  3. Patient pregnant, lactating or breastfeeding or having a positive serum pregnancy test during the screening period
  4. Previous systemic topoisomerase-1 inhibitor treatment (except Topotecan)
  5. History of to monoclonal antibodies, exatecan or of the TUB-040 formulation.

    Note: The excipients of TUB-040 are listed in the IB.

  6. Patients with unresolved malignant bowel obstruction (including patients with radiological findings indicating possible bowel obstruction on CT scans), history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess or Patients on total parenteral nutrition (TPN)
  7. Prior thoracocentesis for therapeutic drainage of malignant effusion \< 4 weeks from trial inclusion and repeated paracentesis for therapeutic drainage of malignant effusion \< 4 weeks before trial inclusion
  8. Prior radiotherapy to the pelvis or abdomen (Dose Escalation phase only)
  9. Patients with serum albumin level \<2,5 g/dL (subjects should not have received IV albumin within 4 weeks of the test)
  10. Participation in interventional clinical studies either concurrently or within the previous 28 days or within 5 half-lives (whichever is shorter) of any pharmacologic agents before study treatment
  11. Patients with untreated spinal cord compression or cerebrovascular accident/stroke within \<6 months of enrollment
  12. Major surgery within 21 days prior to signing the ICF, unless the patient is recovered at that time
  13. History of non-infectious ILD/pneumonitis/radiation pneumonitis that required or has current ILD/pneumonitis
  14. Documented cardiac comorbidities: interval > 470 msec on the screening , unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, uncontrollable hypertension (≥Grade 3), uncontrollable arrhythmias, acute myocarditis, or congestive heart failure (CHF) ( III or IV) or severe aortic stenosis
  15. Active, uncontrolled or severe impairment of the urogenital, renal, hepatobiliary (including liver cirrhosis), cardiovascular, respiratory, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the INV, would predispose the patient to the development of complications from the administration of protocol therapy
  16. Demyelinating diseases: History of multiple sclerosis or of progressive multifocal leukoencephalopathy
  17. History of another with ongoing treatment or not yet free from disease for 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
  18. Any concurrent anti-cancer chemotherapy, radiotherapy (except for local radiation therapy of lesions that may cause imminent complications), hormonal therapy, immunotherapy, or corticosteroid therapy, other than that permitted in Section 8.8.
  19. within 30 days prior to study entry or any known unresolved and active bacterial, viral (e.g. Hep B, Hep C, Varicella or CMV), fungal, mycobacterial, or other infection at screening
  20. History of hypersensitivity to Carbo and risk of further cumulative toxicity with additional platinum, including but not limited to myelosuppression, with febrile neutropenia, Grade 4 hematotoxicity, neuropathy Grade ≥2, renal insufficiency during prior platinum-based therapy
  21. Non-healing wounds, ulcers, or bone fractures
  22. History of posterior reversible encephalopathy syndrome
  23. Recent history of hemoptysis of ≥1/2 teaspoon of red blood within 4 weeks before first study treatment,
  24. History of Grade 4 thromboembolic events
  25. Hypertension ≥ Grade 3 that is not controlled with medical management
  26. proteinuria: urine-protein (UPC) ratio ≥ 1.0 or urine dipstick result ≥ 2+; patients with UPC ratio ≥ 1.0 or ≥ 2+ proteinuria should undergo 24-hour urine collection and must show result \< 1 gram of protein in 24-hour period.
  27. Any patient who is required to take strong inhibitors or inducers (see also Prohibited Medication and Guidance for Potential Use section).

    1. Note: If it is clinically acceptable to replace such medication with a different medication which is not a strong CYP3A4 inhibitor or inducer, then the patient may be eligible.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Phase 1b Dose Escalation

    Drug TUB-040 administered in combination with carboplatin (Carbo) and bevacizumab (BEV)

    Drug: TUB-040 + Carbo + BEV

Interventions

  • DrugTUB-040 + Carbo + BEV

    Drug page: Anti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040

    Ph1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugs

    Occurrence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: From enrollment until 30 days after last study drug

  2. Maximum Tolerated Dose (MTD) of TUB-040 with standard of care (SOC) treatment

    Occurrence of DLTs (Dose limiting toxicities) at different dose levels (during first treatment cycle)

    Time frame: Day 1 up to Day 21 of each treatment cycle

Secondary outcomes

  1. PK Characterization of TUB-040: Cmax

    PK parameters of TUB-040 ADC including maximum concentration Cmax

    Time frame: Day 1 up to Day 21 of each treatment cycle

  2. PK Characterization of TUB-040: Tmax

    PK parameters of TUB-040 ADC including time to Cmax (Tmax)

    Time frame: Day 1 up to Day 21 of each treatment cycle

  3. PK Characterization of TUB-040: AUC

    PK parameters of TUB-040 ADC including area under the curve (AUC)

    Time frame: Day 1 up to Day 21 of each treatment cycle

  4. PK Characterization of TUB-040: t1/2

    PK parameters of TUB-040 ADC including as far as collected data allow an estimation of half-life (t1/2)

    Time frame: Day 1 up to Day 21 of each treatment cycle

  5. Immunogenicity of TUB-040 when used with SOC.

    Incidence and titers of anti-drug antibodies (ADA) against TUB-040

    Time frame: Enrollment to approximately 80 days after last dose.

  6. Preliminary efficacy and safety of TUB-040 with SOC until progression: ORR

    Objective response rate (ORR) by RECIST v1.1 assessed by Investigator (INV)

    Time frame: Enrollment until approximately 80 days since last dose.

  7. Preliminary efficacy and safety of TUB-040 with SOC until progression: TTR

    Time to first response (TTR) by RECIST v1.1 assessed by Investigator (INV)

    Time frame: Enrollment until approximately 80 days since last dose.

  8. Preliminary efficacy and safety of TUB-040 with SOC until progression: DoR

    Duration of response (DoR) by RECIST v1.1 assessed by Investigator (INV)

    Time frame: Enrollment until approximately 80 days since last dose.

  9. Preliminary efficacy and safety of TUB-040 with SOC until progression: PFS

    Progression-free survival (PFS) by RECIST v1.1 assessed by Investigator (INV)

    Time frame: Enrollment until approximately 80 days since last dose.

  10. Preliminary efficacy and safety of TUB-040 with SOC until progression: GCIG

    Number of patients with Gynecologic Cancer Intergroup (GCIG) CA-125 criteria clinical responses

    Time frame: Enrollment until approximately 80 days since last dose.

  11. Preliminary efficacy and safety of TUB-040 with SOC until progression: Incidence SAEs

    Incidence of serious adverse events (SAEs)

    Time frame: Enrollment until approximately 80 days since last dose.

  12. Preliminary efficacy and safety of TUB-040 with SOC until progression: Incidence ≥ Grade 3 lab abnormalities

    Incidence of ≥ Grade 3 laboratory abnormalities

    Time frame: Enrollment until approximately 80 days since last dose.

  13. Evaluate survival rate

    Overall survival (OS) assessed by INV

    Time frame: Enrollment until disease progression (or approximately 24 months)

07

Study locations

7 of 8 sites recruiting
  • Start Cal
    Los Angeles, California 90025, United States
    Recruiting
  • Start Njeb
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Start Nyli
    New York, New York 11042, United States
    Recruiting
  • UCL Louvain
    Brussels, Belgium
    Recruiting
    • UCL Louvain · Contact
  • UZ Gent
    Ghent, Belgium
    Recruiting
    • UZ Gent · Contact
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • UZ Leuven · Contact
  • CHU de Liege
    Liège, Belgium
    Recruiting
    • CHU de Liege · Contact
  • ARENSIA Exploratory Medicine
    Kyiv, Ukraine
    Not yet recruiting
    • ARENSIA Exploratory Medicine · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's planned 24 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 30, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Apr 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07736937
Lead sponsor
Tubulis GmbH
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Mar 30, 2026
Primary completion
Mar 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Tubulis Clinical Trial Inquiries
Contact
ct-inquiries@tubulis.com
+ 49 175 800 5594
Tubulis Medical Director
study director · Tubulis GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040

Start the discussion